Market News How it works Learn FAQ
| RCT 0.0796 4.60% | NU 12.69 -16.29% | EWZ 34.43 -19.16% | BBD 2.935 -27.89% | TGL 0.2399 8.31% | AZTR 1.6199 126.56% | ITUB 7.75 -19.86% | NVD 3.9801 -5.01% | XP 15.9 -47.71% | SRTM 0.2985 -30.63% | WFF 0.0918 14.75% | SHFS 0.0943 -28.78% | SPCX 148.07 0.39% | PBR 22.515 -13.93% | SOXL 92.02 10.12% | VALE 11.96 -3.55% | CLRO 5.015 54.31% | INTC 91.38 5.08% | TSLL 10.875 11.42% | NVDA 216.37 2.56% | GCDT 0.1444 -18.00% | NOK 8.735 7.31% | NWGL 0.089 8.54% | BITO 10.66 -1.57% | SOXS 47.14 -10.14% | CRWV 56.4528 4.09% | RWM 14.485 -0.45% | JBLU 2.345 -10.67% | GPUS 0.1808 7.05% | ABEV 2.835 -14.09% | TSLG 5.44 11.70% | SGRY 23.245 47.59% | AAL 12.2501 1.16% | IREN 25.945 4.18% | INTR 4.6799 -34.91% | SBS 4.69 -26.72% | QID 14.175 -2.58% | TQQQ 68.805 3.79% | RBNE 0.17 -10.53% | T 20.9 -0.14% | SPDN 8.485 -0.64% | TSLA 393.715 5.77% | RIG 6.455 0.70% | WULF 12.225 7.99% | NFLX 63.745 -3.20% | SID 0.9078 -23.07% | LUCD 0.52 26.52% | GRAB 2.692 -3.51% | XTND 2.235 26.27% | PLUG 1.39 0.72%
PCPacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX)

NASDAQ Global Select · Currency in USD
$36.38 ▼ -0.04 (-0.11%)
At close: Oct 26, 4:00 PM ET. Market closed.
$36.38 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:04 PM ET

Summary

Previous Close
$36.42
Open
$36.38
Day's Range
$36.37 – $36.45
52 Week Range
$18.80 – $36.67
Volume
575,958
Avg. Volume
1,037,655
Market Cap
$1.45B
Beta (5Y Monthly)
0.25
PE Ratio (TTM)
103.32
EPS (TTM)
$0.37
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$31.67

Profile: Pacira BioSciences, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
827
CEO
Frank D. Lee
Website
pacira.com

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health. Its offerings include EXPAREL, an injectable liposomal bupivacaine suspension, and ZILRETTA, an extended-release injectable suspension of triamcinolone acetonide. Furthermore, the company offers the iovera system, a non-opioid, handheld cryoanalgesia device capable of delivering precisely controlled cold temperatures to targeted nerves.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.73 · Revenue est. $182.87M
DateEst.Actual
Aug 4, 2026$0.65$0.73Beat
Apr 30, 2026$0.61$0.60Miss
Feb 26, 2026$0.85$0.57Miss
Nov 6, 2025$0.65$0.70Beat
Aug 5, 2025$0.72$0.74Beat
May 8, 2025$0.57$0.62Beat

Analyst view

Consensus price target
$31.67 ▼ -12.9%
Range $25.00 – $36.50
Rating: Hold
Buy 31% · Hold 61% · Sell 8%

Get free alerts on PCRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.